Nepexto 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/12/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IAIN/0029/G 
This was an application for a group of variations. 
15/12/2023 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0024 
B.I.e.2 - Introduction of a post approval change 
14/12/2023 
n/a 
management protocol related to the AS 
PSUSA/10795
Periodic Safety Update EU Single assessment - 
12/10/2023 
11/12/2023 
Refer to Scientific conclusions and grounds recommending 
/202302 
etanercept 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10795/202302. 
II/0023 
B.II.g.2 - Introduction of a post approval change 
26/10/2023 
n/a 
management protocol related to the finished product 
T/0026 
Transfer of Marketing Authorisation 
03/08/2023 
30/08/2023 
SmPC, 
Labelling and 
PL 
IB/0025 
B.II.b.4.f - Change in the batch size (including batch 
07/08/2023 
n/a 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
IB/0021 
B.I.a.2.z - Changes in the manufacturing process of 
12/07/2023 
n/a 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Other variation 
IB/0022 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
11/07/2023 
30/08/2023 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0019 
B.I.e.5.c - Implementation of changes foreseen in an 
05/05/2023 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/01/2023 
30/08/2023 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/09/2022 
14/10/2022 
SmPC and PL 
To update section 5.1 of the SmPC in order to update 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0016 
B.II.b.5.z - Change to in-process tests or limits 
20/06/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0014/G 
This was an application for a group of variations. 
15/03/2022 
n/a 
clinical information based on final results obtained from a 
clinical paediatric study. 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IA/0015/G 
This was an application for a group of variations. 
14/03/2022 
14/10/2022 
Annex II and 
PL 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0011 
B.I.e.2 - Introduction of a post approval change 
02/12/2021 
n/a 
management protocol related to the AS 
IAIN/0013/G 
This was an application for a group of variations. 
01/10/2021 
14/10/2022 
SmPC, Annex 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
II, Labelling 
and PL 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.IV.1.b - Change of a measuring or administration 
device - Deletion of a device 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0012 
B.I.a.1.z - Change in the manufacturer of AS or of a 
29/09/2021 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0010/G 
This was an application for a group of variations. 
16/09/2021 
n/a 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.II.b.4.f - Change in the batch size (including batch 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of the finished product - Tightening of 
specification limits 
II/0002 
B.II.b.1.d - Replacement or addition of a 
24/06/2021 
n/a 
manufacturing site for the FP - Site which requires an 
initial or product specific inspection 
IB/0009/G 
This was an application for a group of variations. 
05/05/2021 
21/06/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0008 
B.I.a.2.a - Changes in the manufacturing process of 
25/03/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IA/0007/G 
This was an application for a group of variations. 
16/02/2021 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.5.a - Change to in-process tests or limits 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.I.c.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Addition of a new specification parameter to the 
specification with its corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0006 
C.I.11.z - Introduction of, or change(s) to, the 
21/01/2021 
21/06/2021 
SmPC, Annex 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II and PL 
IB/0005 
B.I.b.2.z - Change in test procedure for AS or 
09/11/2020 
n/a 
starting material/reagent/intermediate - Other 
variation 
IAIN/0004 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/10/2020 
21/06/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II and PL 
IAIN/0003 
B.II.e.5.a.1 - Change in pack size of the finished 
09/09/2020 
21/06/2021 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IB/0001 
B.II.e.5.a.2 - Change in pack size of the finished 
07/07/2020 
21/06/2021 
SmPC, 
product - Change in the number of units (e.g. 
Labelling and 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change outside 
PL 
the range of the currently approved pack sizes 
Page 8/8 
 
 
 
 
 
 
 
